Intellia Therapeutics, Inc. (NTLA)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$11.21+0.45%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Intellia Therapeutics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	17.06M
EPS	—	-0.768
Annual ending 2026-12-31
Revenue	—	50.26M
EPS	—	-3.199
Annual ending 2027-12-31
Revenue	—	121.15M
EPS	—	-2.626

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Advance Lonvo-z for hereditary angioedema treatment	Intellia is advancing Lonvo-z for hereditary angioedema treatment.	Recovered	Progress stalls or trial results turn negative	BLA accepted with PDUFA date Mar 10, 2027 vs Phase 3 progress target FDA accepted Lonvo-z BLA on Sept 8, 2026, granting priority review with a March 10, 2027 PDUFA target date. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Management reported positive Phase 3 HAELO trial results showing lonvo-z reduced attacks by 87% versus placebo with a mean monthly attack rate of 0.26 vs. 2.10, and 62% of patients were attack free and therapy free versus 11% placebo. The rolling BLA submission was initiated and FDA acceptance is anticipated in second half of 2026 with a planned U.S. launch in first half of 2027. The trajectory is delivering on clinical and regulatory milestones. Delivery assessment Oct 24, 2026
Extend cash runway into 2028	The company aims to extend cash to 2028.	Improving	Cash runway falls short of 2028	Cash runway extended into 2028 via $400M facility NTLA secured a $400M credit agreement with OrbiMed to extend cash runway into 2028. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Cash, cash equivalents and marketable securities increased from $605.1 million at 2025-Q4 to $628.4 million at 2026-Q2. Management consistently states that existing cash resources are expected to fund operations at least into 2028 and beyond lonvo-z's anticipated U.S. commercial launch in first half of 2027. The trajectory shows stable to improving cash position supporting this priority. Delivery assessment Oct 24, 2026
Achieve revenue above $67 million in 2026	Revenue is expected above $67 million in 2026.	Intact	Revenue falls below $67 million in FY26	Revenue: $7.659M FY2026-Q2; GAAP. Published target: >= $67.67 million. Target period is not explicitly aligned with this observation. Source published Aug 6, 20267,659,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 899fc751-152a-46f3-8453-4257a97a6096. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-2.63

$-1.82 → $-2.63 · observed estimates

FY2027 revenue$0.12B

$0.27B → $0.12B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-1.82	$271,882,869	13 / 14
2026-07-25	$-1.76	$268,415,400	17 / 18
2026-07-26	$-1.76	$268,415,400	17 / 18
2026-07-27	$-1.76	$268,415,400	17 / 18
2026-07-28	$-1.82	$271,882,869	13 / 14
2026-07-29	$-1.76	$268,415,400	17 / 18
2026-07-30	$-1.76	$268,415,400	17 / 18
2026-07-31	$-1.76	$268,415,400	17 / 18
2026-08-01	$-1.82	$271,882,869	13 / 14
2026-08-02	$-1.73	$273,622,190	16 / 17
2026-08-03	$-1.82	$271,882,869	13 / 14
2026-08-04	$-1.82	$271,882,869	13 / 14
2026-08-05	$-1.73	$273,622,190	16 / 17
2026-08-06	$-1.82	$271,882,869	13 / 14
2026-08-07	$-1.79	$277,631,799	13 / 13
2026-08-08	$-1.73	$339,509,940	16 / 13
2026-08-09	$-1.73	$339,509,940	16 / 13
2026-08-10	$-1.73	$339,509,940	16 / 13
2026-08-12	$-2.56	$125,471,390	16 / 17
2026-08-13	$-1.79	$277,631,799	13 / 13
2026-08-14	$-1.79	$277,631,799	13 / 13
2026-08-15	$-1.79	$277,631,799	13 / 13
2026-08-16	$-1.79	$277,631,799	13 / 13
2026-08-17	$-1.79	$277,631,799	13 / 13
2026-08-18	$-1.79	$277,631,799	13 / 13
2026-08-19	$-1.79	$277,631,799	13 / 13
2026-08-20	$-2.67	$120,324,722	13 / 13
2026-08-21	$-2.67	$120,324,722	13 / 13
2026-08-22	$-2.67	$120,324,722	13 / 13
2026-08-23	$-2.67	$120,324,722	13 / 13
2026-08-24	$-2.67	$120,324,722	13 / 13
2026-08-25	$-2.67	$120,324,722	13 / 13
2026-08-26	$-2.67	$120,324,722	13 / 13
2026-08-27	$-2.67	$120,324,722	13 / 13
2026-08-28	$-2.67	$120,324,722	13 / 13
2026-08-29	$-2.67	$120,324,722	13 / 13
2026-08-30	$-2.67	$120,324,722	13 / 13
2026-08-31	$-2.67	$120,324,722	13 / 13
2026-09-01	$-2.67	$120,324,722	13 / 13
2026-09-02	$-2.67	$120,324,722	13 / 13
2026-09-03	$-2.67	$120,324,722	13 / 13
2026-09-04	$-2.67	$120,324,722	13 / 13
2026-09-05	$-2.67	$120,324,722	13 / 13
2026-09-06	$-2.67	$120,324,085	13 / 13
2026-09-07	$-2.67	$120,324,085	13 / 13
2026-09-08	$-2.67	$120,324,085	13 / 13
2026-09-09	$-2.66	$120,780,335	13 / 13
2026-09-10	$-2.66	$121,156,641	13 / 13
2026-09-11	$-2.66	$121,156,641	13 / 13
2026-09-12	$-2.66	$121,156,641	13 / 13
2026-09-13	$-2.66	$121,156,641	13 / 13
2026-09-14	$-2.66	$121,156,641	13 / 13
2026-09-15	$-2.66	$121,156,641	13 / 13
2026-09-16	$-2.66	$121,156,641	13 / 13
2026-09-17	$-2.66	$121,156,641	13 / 13
2026-09-18	$-2.66	$121,156,641	13 / 13
2026-09-19	$-2.66	$121,156,641	13 / 13
2026-09-20	$-2.66	$121,156,641	13 / 13
2026-09-21	$-2.66	$121,156,641	13 / 13
2026-09-22	$-2.66	$121,156,641	13 / 13
2026-09-23	$-2.66	$121,156,641	13 / 13
2026-09-24	$-2.66	$121,156,641	13 / 13
2026-09-25	$-2.66	$121,156,641	13 / 13
2026-09-26	$-2.66	$121,156,641	13 / 13
2026-09-27	$-2.66	$121,156,641	13 / 13
2026-09-28	$-2.66	$121,156,641	13 / 13
2026-09-29	$-2.66	$121,156,641	13 / 13
2026-09-30	$-2.66	$121,156,641	13 / 13
2026-10-01	$-2.66	$121,156,641	13 / 13
2026-10-02	$-2.66	$121,156,641	13 / 13
2026-10-03	$-2.66	$121,154,414	13 / 13
2026-10-04	$-2.66	$121,154,414	13 / 13
2026-10-05	$-2.66	$121,154,414	13 / 13
2026-10-06	$-2.66	$121,154,414	13 / 13
2026-10-07	$-2.66	$121,154,414	13 / 13
2026-10-08	$-2.63	$121,154,414	13 / 13
2026-10-09	$-2.63	$121,154,414	13 / 13
2026-10-10	$-2.63	$121,154,414	13 / 13
2026-10-11	$-2.63	$121,154,414	13 / 13
2026-10-12	$-2.63	$121,154,414	13 / 13
2026-10-13	$-2.63	$121,154,414	13 / 13
2026-10-14	$-2.63	$121,154,414	13 / 13
2026-10-15	$-2.63	$121,154,414	13 / 13
2026-10-16	$-2.63	$121,154,416	13 / 13
2026-10-17	$-2.63	$121,154,416	13 / 13
2026-10-18	$-2.63	$121,154,416	13 / 13
2026-10-19	$-2.63	$121,154,416	13 / 13
2026-10-20	$-2.63	$121,154,416	13 / 13
2026-10-21	$-2.63	$121,154,416	13 / 13
2026-10-22	$-2.63	$121,154,416	13 / 13
2026-10-23	$-2.63	$121,154,416	13 / 13
2026-10-24	$-2.63	$121,154,416	13 / 13

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	15	9	2
2026-06-01	13	9	2
2026-07-01	12	8	3
2026-08-01	10	7	3
2026-09-01	10	6	3
2026-10-01	10	6	4

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 10 Buy / Strong Buy · 6 Hold · 4 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

BarclaysOct 6

$8.00New observation · no comparable prior

$0$4.40$8.80

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Achieve revenue above $67 million in 2026Revenue: $7.659M

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

1 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.3%Typical daily move · historical

Downside history

-69.0%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Intellia Therapeutics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative clinical-stage biotechnology business, not yet a profitable compounder. The long-term thesis is on watch: lonvo-z is meeting clinical and regulatory milestones, but execution is still uncertain and overall risk is elevated.

What's priced into Intellia Therapeutics, Inc.

The available valuation model shows NTLA at a durable premium to peers, while expectations appear demanding; model confidence is low. The priced-in assessment is tagged as justified, with no fragility gates triggered, but the evidence does not explain the premium in detail.

What the fundamentals likely do

Near term, the company is likely to remain loss-making, while reported performance is neutral and below its industry cohort. Management is on track with lonvo-z and cash runway priorities, with resources expected to fund operations into 2028; nex-z trial progress is mixed. A guidance cut or continued weak results across industry peers are risks into the next report.

What Intellia Therapeutics, Inc. hinges on

Over the next one to three years, a key swing factor is whether lonvo-z receives FDA acceptance and reaches its planned U.S. launch in the first half of 2027. Nex-z enrollment and trial progress, cash runway, and management execution also matter. Healthcare sector strength could support the backdrop, while weaker economic data or a guidance cut could weigh on the business outlook.